Strongbridge Biopharma Current Ratio 2014-2021 | SBBP

Strongbridge Biopharma current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Strongbridge Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.07B $0.02B 3.00
2021-03-31 $0.08B $0.02B 3.63
2020-12-31 $0.09B $0.02B 4.37
2020-09-30 $0.09B $0.02B 4.51
2020-06-30 $0.07B $0.02B 3.39
2020-03-31 $0.07B $0.02B 2.86
2019-12-31 $0.08B $0.02B 3.44
2019-09-30 $0.09B $0.02B 4.24
2019-06-30 $0.10B $0.02B 5.31
2019-03-31 $0.12B $0.02B 5.15
2018-12-31 $0.13B $0.02B 7.67
2018-09-30 $0.08B $0.02B 3.38
2018-06-30 $0.09B $0.01B 6.46
2018-03-31 $0.10B $0.01B 8.89
2017-12-31 $0.06B $0.01B 4.87
2017-09-30 $0.05B $0.01B 4.70
2017-06-30 $0.04B $0.01B 4.63
2017-03-31 $0.05B $0.01B 5.21
2016-12-31 $0.07B $0.02B 4.24
2016-09-30 $0.03B $0.00B 6.08
2016-06-30 $0.03B $0.01B 7.10
2016-03-31 $0.04B $0.01B 7.07
2015-12-31 $0.05B $0.01B 9.65
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.02B $0.00B 7.06
2013-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.140B $0.031B
Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71